A leading supplier of novel protein measurement technology to accelerate the development of diagnostic and clinical applications, and biological and pharmaceutical products, today announced the launch of a new ViBE software v3 allowing use of the platform in GLP and drug development labs. The new software, enabling faster plate read times of one hour, lower reagent consumption, FDA 21 CFR Part 11 tools and LIMS connectivity, was introduced at the recently concluded Protein Engineering Summit (PEGS) conference in Boston.

“The new software allows customers to deploy the ViBE platform in phase 1 clinical studies and other GLP labs in drug development and QC. The ViBE platform, paired with our non-optical Acoustic Assays™, overcomes limitations of traditional methods like ELISA or Western blot by providing a simple, highly sensitive method of measuring specific proteins in a complex sample, with walk-away automation,” said Christopher Silva, Vice President, Commercial Operations at BioScale. “This will be particularly important for scientists needing to study immunologic interferences, pharmacokinetic profiling, and toxicity as part of their IND program in the areas of oncology, CNS, cardiovascular and inflammation research – areas where the platform is currently utilized.”

BioScale’s ViBE platform enables non-optical, acoustic protein measurement utilizing BioScale’s proprietary AMMP® (Acoustic Membrane MicroParticle) technology. The company’s Acoustic Assays measure analyte concentration by determining changes in oscillation frequency caused by the binding of microparticles to the sensor surface. The platform features 1-, 2- 3- and 6-plate assay formats allowing analysis of up to 576 samples per cartridge.

“At the PEGS conference, data from the platform summarizing development of a generic anti-PEG immunogenicity assay was presented by scientists from Bristol Myers Squib, highlighting that none of the existing technologies could deliver the required assay sensitivity.” concludedSilva.

About BioScale, Inc.
BioScale manufactures and markets the ViBE® platform, a novel protein measurement technology enabling highly sensitive, automated Acoustic Immunoassays™. The company is dedicated to bringing its innovative technology to diagnostic, clinical and drug development applications to enhance human health. The platform’s ease of use, sensitivity, precision and reproducibility as well as the unique ability to measure validated as well as challenging emerging biomarkers directly in complex biological and clinical samples provide key competitive advantages to address unmet needs in clinical research and diagnostics. The company’s instrumentation platform is used by leading biopharmaceutical companies and academic institutions. BioScale is headquartered in Billerica, Mass.